Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
at www.tipranks.com (Wed, 18-Mar 3:36 AM)
Most oversold mid-cap healthcare stocks on Wall Street amid Middle East disruptions
at seekingalpha.com (Tue, 17-Mar 10:40 AM)
Amneal Exceeds 2025 Guidance and Eyes More Growth for 2026 as Portfolio Strengthens
Market Chameleon (Fri, 27-Feb 9:21 AM)
AMRX to Join S&P SmallCap 600 Amid Index Shuffle: What the Move Means for Investors
Market Chameleon (Wed, 28-Jan 9:29 AM)
